Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manreet Kanwar

Advanced Heart Failure and Transplant Cardiology Chicago, IL Medical Doctor

NPI 1477787257 CMS profile 202620

5841 S Maryland Ave, Chicago, IL 60637

Open in the dashboard

General payments

$162,488

241 records reported · program years 2019–2025

Research payments

$137

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$314,956 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Manreet Kanwar of Chicago, IL is reported in the CMS Open Payments database as having received $162,488 across 241 general payments and $137 in research payments paid to them. Separately, studies naming them as principal investigator received $314,956 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69,468 78
2024 General $29,582 39
2023 General $23,158 52
2023 Research $137 1
2022 General $7,448 18
2021 General $15,082 20
2020 General $5,103 8
2019 General $12,647 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manreet Kanwar
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Manreet Kanwar were reported at $69,468. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Manreet Kanwar Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $12,647 $863 $224–$4,562 $163
2020 $5,103 $452 $122–$3,992 $114
2021 $15,082 $550 $159–$3,571 $132
2022 $7,448 $729 $221–$4,357 $149
2023 $23,158 $1,002 $309–$5,827 $160
2024 $29,582 $931 $273–$5,204 $164
2025 $69,468 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $83,204 100 payments
  2. Abbott Laboratories $70,137 96 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $6,852 6 payments
  4. Ancora Heart, Inc. $854 5 payments
  5. Impulse Dynamics (USA) Inc. $174 10 payments
  6. Edwards Lifesciences Corporation $166 2 payments
  7. LivaNova USA, Inc. $145 2 payments
  8. Endotronix, Inc. $138 1 payment
  9. Medtronic, Inc. $130 1 payment
  10. CVRx, Inc. $124 2 payments
  11. Other $563 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $74,754 31 payments
  2. Honoraria $50,350 17 payments
  3. Travel and Lodging $24,781 55 payments
  4. Food and Beverage $10,203 137 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,400 1 payment
Products named General payments · program years 2019–2025
  1. Impella $74,743 77 payments
  2. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $36,115 39 payments
  3. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $8,814 38 payments
  4. Adempas $6,852 6 payments
  5. CARDIOMEMS $6,059 8 payments
  6. AccuCinch $854 5 payments
  7. HeartMate 3 Left Ventricular Dev $319 3 payments
  8. ProtekDuo $145 2 payments
  9. CORDELLA PULOMONARY ARTERY PRESSURE SENSOR $138 1 payment
  10. OPTIMIZER $136 8 payments
  11. Other $1,428 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $137 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

2,670

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$4,332,662

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

32.8%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Adempas Riociguat Brand 85 $1,160,607
Opsumit Macitentan Brand 84 $1,057,437
Uptravi Selexipag Brand 40 $902,777
Tyvaso Dpi Treprostinil Brand 13 $304,769
Entresto Sacubitril/Valsartan Brand 216 $185,685
Ambrisentan Generic 54 $170,974
Letairis Ambrisentan Brand 12 $143,332
Jardiance Empagliflozin Brand 173 $120,126
Eliquis Apixaban Brand 127 $111,214
Tadalafil Generic 37 $55,807

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$25,132

Medicare's payments for the services billed

Medicare patients

103

Average age 71

Services billed

271

40 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 69%
Atrial fibrillation 56%
Chronic kidney disease 56%
Arthritis 52%
Diabetes 49%
COPD 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $18
$18 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $18
$18 216 —
CYTOGAM
  • Kamada Ltd. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record